Figure 4

Network centrality impact of the classified CaI proteins upon drug statuses. (a) The distribution of the centrality measures of betweenness (BC), degree (DC) and Eigenvector (EC) for the classified R proteins in the x-axis: R1, n = 2422; R2, n = 3953; R3, n = 1272; R4, n = 400; R5, n = 33; R6, n = 63; and R7, n = 34. The mean is shown through the box and whisker plot. (b) The mean distribution of the BC, DC and EC measures for the classified R proteins having WOC and WCT statuses for the drugs developed against them in the x-axis. For WOC: R1, n = 2249; R2, n = 3355; R3, n = 1022; R4, n = 287; R5, n = 28; R6, n = 35; and R7, n = 19 and for WCT: R1, n = 173; R2, n = 598; R3, n = 250; R4, n = 113; R5, n = 5; R6, n = 28; and R7, n = 15. (c) Impact of centrality measures on the individual drug statuses of the classified R group proteins. X-axis represents different drug statuses: Not Available (N/A; n = 6193), Experimental (Exp; n = 287), Nutraceutical (NUT; n = 515), Investigational (Inv; n = 144), Approved (APP; n = 837), Illicit (ILL; n = 20), and Withdrawn (WD; n = 181). Only the statistical comparison between APP and WD are shown in the graph (refer to Supplementary Table 2 for more in-depth statistical results). Y-axis of the graphs represents centrality measures BC, DC and EC for respective panels in rows. Error bars = standard error, *p < 0.05, **p < 0.01, ***p < 0.001.